Insmed Up Over 30% Following FDA Decision
Arikayce is designed to treat lung infections; more specifically, nontuberculous mycobacterial lung disease.
Insmed further stated that the designation was based on results from the phase two trial and the company plans to meet with the FDA to form a regulation pathway.
Shares were last trading at $16.65, a 33.57 percent gain.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.